SEZL Jumps 15.6% as EPS Revisions Fuel Fintech Rally; NVAX, RZLT, SNAP Follow
Sezzle (SEZL) led today's EPS-revision-driven gainers, surging 15.6% to $130.48 after reporting a next-year EPS growth estimate of 27.3% and setting its Q3 earnings date. Novavax (NVAX) climbed 12.8% on a 20-percentage-point upward revision to its next-year EPS growth estimate (77.3% to 97.3%), while Rezolute (RZLT) added 12.7% after an FDA pre-BLA meeting nod, and Snap (SNAP) rose 12.4% on a 12-point EPS estimate bump and activist pressure.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| SEZL | Financial | 2026-10-06 | N/A | +15.6% |
| NVAX | Healthcare | 2026-10-07 | +20.0pp | +12.8% |
| RZLT | Healthcare | 2026-10-06 | +1.7pp | +12.7% |
| SNAP | Communication Services | 2026-10-07 | +12.0pp | +12.4% |
| PRCT | Healthcare | 2026-10-05 | N/A | +9.8% |
Why did SEZL stock jump in October 2026?
SEZL jumped 15.6% (from $112.84 to $130.48) after analysts raised its next-year EPS growth estimate to 27.3% on October 6, with momentum building into the October 8 Q3 earnings announcement.
TD Cowen lowered its price target on Sezzle as part of a consumer finance earnings preview, but the stock's 77% year-to-date gain and upcoming investor conferences (BMO, Citi, KBW, TD Cowen) reinforced positive sentiment. The detected EPS revision signaled improving profitability expectations for the buy-now-pay-later sector, and the market confirmed with a double-digit rally ahead of Q3 results on November 4.
SEZL EPS revision history → · Screener snapshot from 2026-10-06 →
FAQ: SEZL
Why did SEZL stock jump?
SEZL jumped 15.6% to $130.48 after its next-year EPS growth estimate was revised to 27.3% on October 6, combined with the announcement of its Q3 earnings date and upcoming investor conferences.
Is SEZL a buy after the rally?
SEZL has gained 77% year-to-date, and TD Cowen recently lowered its price target, suggesting mixed analyst sentiment. The upcoming Q3 earnings on November 4 will be a key catalyst for direction.
What is SEZL's EPS growth estimate?
Sezzle's next-year EPS growth estimate is 27.3% as of the October 2026 revision.
Why did NVAX stock jump in October 2026?
NVAX jumped 12.8% (from $11.22 to $12.66) after analysts raised its next-year EPS growth estimate from 77.3% to 97.3% on October 7, a 20-percentage-point upward revision.
The surge occurred without company-specific news, pointing to sector-driven momentum in vaccine and biotech stocks. The EPS revision reflects expectations of sharply higher profitability, and the market responded with a double-digit gain as investors positioned for potential upside ahead of the company's next earnings report.
NVAX EPS revision history → · Screener snapshot from 2026-10-07 →
FAQ: NVAX
Why did NVAX stock jump?
NVAX jumped 12.8% from $11.22 to $12.66 after its next-year EPS growth estimate was revised upward from 77.3% to 97.3% on October 7, 2026.
Is NVAX a buy after the rally?
The sharp upward EPS revision to 97.3% growth suggests improving profitability expectations, but the absence of company-specific news means sector trends are likely driving the move. Investors should watch for the next earnings report for confirmation.
What is NVAX's EPS growth estimate?
Novavax's next-year EPS growth estimate is 97.3%, up from a previous estimate of 77.3%.
Why did RZLT stock jump in October 2026?
RZLT surged 12.7% (from $4.32 to $4.87) after its next-year EPS growth estimate was raised from 25.6% to 27.3% on October 6, following an FDA recommendation for a pre-BLA meeting.
The FDA nod on October 5 for Ersodetug in congenital hyperinsulinism came despite a Phase 3 miss, as additional glucose-monitoring data supported a path to filing. The ongoing open-label extension showing continued blood sugar control reinforced the regulatory update, and the EPS revision confirmed that analysts see a viable commercial future for the drug.
RZLT EPS revision history → · Screener snapshot from 2026-10-06 →
FAQ: RZLT
Why did RZLT stock jump?
RZLT jumped 12.7% from $4.32 to $4.87 after the FDA recommended a pre-BLA meeting for Ersodetug on October 5, and its next-year EPS growth estimate was revised from 25.6% to 27.3% on October 6.
What caused RZLT's surge?
The surge was caused by the FDA's recommendation for a Type B pre-BLA meeting for Ersodetug in congenital hyperinsulinism, despite the Phase 3 sunRIZE study missing primary endpoints, combined with a positive EPS estimate revision.
Is RZLT a buy after the rally?
The FDA pre-BLA meeting is a positive regulatory signal, but the Phase 3 miss remains a risk. The next catalyst will be the outcome of that meeting and any BLA submission.
Why did SNAP stock jump in October 2026?
SNAP jumped 12.4% (from $5.81 to $6.53) after analysts raised its next-year EPS growth estimate from 399.7% to 411.7% on October 7, a 12-point upward revision.
Activist investor Blue Duck Capital urged the board to raise external capital for Specs on October 6, arguing it could unlock a sum-of-the-parts re-rating to $12–14 per share and remove $500 million in annual spending from the core business. The company also announced its Q3 results date on October 8, adding to the positive news flow. The extreme EPS growth estimate reflects a low base, but the market focused on the potential value unlock.
SNAP EPS revision history → · Screener snapshot from 2026-10-07 →
FAQ: SNAP
Why did SNAP stock jump?
SNAP jumped 12.4% from $5.81 to $6.53 after its next-year EPS growth estimate was revised from 399.7% to 411.7% on October 7, and activist Blue Duck Capital pushed for a Specs spinoff on October 6.
What caused SNAP's surge?
The surge was driven by a combination of a 12-point upward EPS estimate revision and an open letter from Blue Duck Capital urging Snap to raise external capital for Specs, which could unlock $5 billion in value.
What is SNAP's EPS growth estimate?
Snap's next-year EPS growth estimate is 411.7%, up from a previous estimate of 399.7%.
Why did PRCT stock jump in October 2026?
PRCT gained 9.8% (from $17.82 to $19.57) after its next-year EPS growth estimate was set at 32.1% on October 5, and the company announced its Q3 earnings date for November 4 on October 12.
The surgical robotics company, focused on urology with its HYDROS system, benefited from positive sector sentiment and a favorable analyst mention. The EPS revision signaled confidence in Procept's path to profitability, and the stock rallied ahead of its earnings report as investors anticipated strong results.
PRCT EPS revision history → · Screener snapshot from 2026-10-05 →
FAQ: PRCT
Why did PRCT stock jump?
PRCT jumped 9.8% from $17.82 to $19.57 after its next-year EPS growth estimate was set at 32.1% on October 5, and the company scheduled its Q3 earnings for November 4.
Is PRCT a buy after the rally?
The 32.1% next-year EPS growth estimate and upcoming Q3 earnings on November 4 are key catalysts. However, the stock remains volatile, and investors should watch for execution on its robotic surgery platform.
What is PRCT's EPS growth estimate?
PROCEPT BioRobotics' next-year EPS growth estimate is 32.1% as of the October 2026 revision.
Today's double-digit gains in SEZL, NVAX, RZLT, and SNAP highlight the market's strong reaction to upward EPS estimate revisions, particularly in fintech and healthcare, where regulatory and sector catalysts amplified the moves. This suggests investors are rewarding companies with improving profitability outlooks ahead of Q3 earnings season.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →